Xenon anesthesia: shedding light on brain dynamics and clinical niches

PURPOSE OF REVIEW: Xenon is reemerging as a clinically attractive inhalational anesthetic because it combines rapid kinetics and cardiovascular stability with mechanism features that differ from GABAergic agents. Simultaneously, new membrane-biophysics and systems-neuroscience data are reshaping how models in anesthetic state transitions worked, which expands the future of how anesthetic agents are used. RECENT FINDINGS: Contemporary work strengthens the view that xenon acts primarily via noncompetitive NMDA receptor inhibition, with additional effects on excitability-related ion channels. Whole-cortex modeling and high-density electroencephalogram studies link xenon sedation to reduced long-range coupling, slowed alpha peak frequency, increased damping of alpha-band dynamics, and a shift toward more stable population dynamics that track response better than gas concentration. Despite this, xenon's studies do not show a consistent reduction in postoperative neurocognitive disorders. However, xenon has been shown to accelerate early recovery anesthesia times. SUMMARY: Though definitive outcome benefits remain unproven, xenon's value may represent a reemergent inhalational drug as the environmental carbon dioxide footprint is very attractive. Besides, the rapid recovery of xenon's general anesthesia, is also a distinct, quantifiable systems-level physiology that can guide depth monitoring and motivate targeted trials, improving the design and protocol of the studies in high-risk neurocognitive and brain-injury settings.